  |
 | Up a level |
Plimack, Elizabeth R. and Rini, Brian I. and Stus, Viktor and Gafanov, Rustem and Waddell, Tom and Nosov, Dmitry and Pouliot, Frédéric and Soulieres, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L. Rhoda and Atkins, Michael B. and Powles, Thomas (2020) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology, Vol.38 (15supp). p. 5001. ISSN 1527-7755 (online, version of record) and 0732-183X (print)
Powles, Thomas and Plimack, Elizabeth R. and Soulieres, Denis and Waddell, Tom and Stus, Viktor and Gafanov, Rustem and Nosov, Dmitry and Pouliot, Frédéric and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio J and Borchiellini, Delphine and McDermott, Raymond S and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L Rhoda and Atkins, Michael B and Rini, Brian I (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology, 21 (No. 12). pp. 1563-73. ISSN 1470-2045
